Etanercept biosimilar (Hisun-Pfizer Pharmaceuticals)

依那西普生物类似药 (Hisun-Pfizer Pharmaceuticals)

Report date: 2024/06/27 15:02:36

Base Information

Drug NameEtanercept biosimilar (Hisun-Pfizer Pharmaceuticals)
Drug Alias NameEtanercept (Hisun-Pfizer Pharmaceuticals)益赛普生物仿制药 (Hisun-Pfizer Pharmaceuticals)依那西普生物仿制药 (Hisun-Pfizer Pharmaceuticals)Etanerceptum (Hisun-Pfizer Pharmaceuticals)融合蛋白生物仿制药 (Hisun-Pfizer Pharmaceuticals) +[7] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Global Approved IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Approved Indications in ChinaPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Original Approved Country/TerritoryMainland China
Original Approved Date2010/02/26
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHisun-Pfizer
China Registration ClassN/A

Develop Information

Active CompaniesWyeth Europa Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A